130 related articles for article (PubMed ID: 8271954)
21. Selective localization of receptors for urokinase amino-terminal fragment at substratum contact sites of an in vitro-established line of human epidermal cells.
Del Rosso M; Pedersen N; Fibbi G; Pucci M; Dini G; Anichini E; Blasi F
Exp Cell Res; 1992 Dec; 203(2):427-34. PubMed ID: 1333982
[TBL] [Abstract][Full Text] [Related]
22. Intermolecular contact regions in urokinase plasminogen activator receptor.
Liang OD; Bdeir K; Matz RL; Chavakis T; Preissner KT
J Biochem; 2003 Nov; 134(5):661-6. PubMed ID: 14688231
[TBL] [Abstract][Full Text] [Related]
23. Determination of the levels of urokinase and its receptor in human colon carcinoma cell lines.
Boyd D; Florent G; Kim P; Brattain M
Cancer Res; 1988 Jun; 48(11):3112-6. PubMed ID: 2835152
[TBL] [Abstract][Full Text] [Related]
24. Domain interplay in the urokinase receptor. Requirement for the third domain in high affinity ligand binding and demonstration of ligand contact sites in distinct receptor domains.
Behrendt N; Ronne E; Dano K
J Biol Chem; 1996 Sep; 271(37):22885-94. PubMed ID: 8798468
[TBL] [Abstract][Full Text] [Related]
25. Positive regulation of activation of plasminogen by urokinase: differences in Km for (glutamic acid)-plasminogen and lysine-plasminogen and effect of certain alpha, omega-amino acids.
Peltz SW; Hardt TA; Mangel WF
Biochemistry; 1982 May; 21(11):2798-804. PubMed ID: 6212078
[No Abstract] [Full Text] [Related]
26. Carboxy-terminal processing of the urokinase receptor: implications for substrate recognition and glycosylphosphatidylinositol anchor addition.
Aceto J; Kieber-Emmons T; Cines DB
Biochemistry; 1999 Jan; 38(3):992-1001. PubMed ID: 9893995
[TBL] [Abstract][Full Text] [Related]
27. Recombinant soluble urokinase receptor as a scavenger for urokinase-type plasminogen activator (uPA). Inhibition of proliferation and invasion of human ovarian cancer cells.
Wilhelm O; Weidle U; Höhl S; Rettenberger P; Schmitt M; Graeff H
FEBS Lett; 1994 Jan; 337(2):131-4. PubMed ID: 8287966
[TBL] [Abstract][Full Text] [Related]
28. The ligand-binding domain of the cell surface receptor for urokinase-type plasminogen activator.
Behrendt N; Ploug M; Patthy L; Houen G; Blasi F; Danø K
J Biol Chem; 1991 Apr; 266(12):7842-7. PubMed ID: 1850423
[TBL] [Abstract][Full Text] [Related]
29. Specific binding of urinary-type plasminogen activator (u-PA) to vitronectin and its role in mediating u-PA-dependent adhesion of U937 cells.
Moser TL; Enghild JJ; Pizzo SV; Stack MS
Biochem J; 1995 May; 307 ( Pt 3)(Pt 3):867-73. PubMed ID: 7537960
[TBL] [Abstract][Full Text] [Related]
30. Differentiation-enhanced binding of the amino-terminal fragment of human urokinase plasminogen activator to a specific receptor on U937 monocytes.
Stoppelli MP; Corti A; Soffientini A; Cassani G; Blasi F; Assoian RK
Proc Natl Acad Sci U S A; 1985 Aug; 82(15):4939-43. PubMed ID: 2991901
[TBL] [Abstract][Full Text] [Related]
31. One-step affinity purification of recombinant urokinase-type plasminogen activator receptor using a synthetic peptide developed by combinatorial chemistry.
Jacobsen B; Gårdsvoll H; Juhl Funch G; Ostergaard S; Barkholt V; Ploug M
Protein Expr Purif; 2007 Apr; 52(2):286-96. PubMed ID: 17027282
[TBL] [Abstract][Full Text] [Related]
32. Systematic mutational analysis of the receptor-binding region of the human urokinase-type plasminogen activator.
Magdolen V; Rettenberger P; Koppitz M; Goretzki L; Kessler H; Weidle UH; König B; Graeff H; Schmitt M; Wilhelm O
Eur J Biochem; 1996 May; 237(3):743-51. PubMed ID: 8647121
[TBL] [Abstract][Full Text] [Related]
33. Growth stimulation of human epidermal cells by urokinase is restricted to the intact active enzyme.
Kirchheimer JC; Christ G; Binder BR
Eur J Biochem; 1989 Apr; 181(1):103-7. PubMed ID: 2540964
[TBL] [Abstract][Full Text] [Related]
34. Two distinct pathways of the streptokinase-mediated activation of highly purified human plasminogen.
McClintock DK; Englert ME; Dziobkowski C; Snedeker EH; Bell PH
Biochemistry; 1974 Dec; 13(26):5334-44. PubMed ID: 4279693
[No Abstract] [Full Text] [Related]
35. Characterization of the binding of urokinase-type plasminogen activator (u-PA) to plasminogen, to plasminogen-activator inhibitor-1 and to the u-PA receptor.
Lijnen HR; De Cock F; Collen D
Eur J Biochem; 1994 Sep; 224(2):567-74. PubMed ID: 7925373
[TBL] [Abstract][Full Text] [Related]
36. Alveolar macrophage urokinase receptors localize enzyme activity to the cell surface.
Chapman HA; Bertozzi P; Sailor LZ; Nusrat AR
Am J Physiol; 1990 Dec; 259(6 Pt 1):L432-8. PubMed ID: 2175557
[TBL] [Abstract][Full Text] [Related]
37. Cyclo19,31[D-Cys19]-uPA19-31 is a potent competitive antagonist of the interaction of urokinase-type plasminogen activator with its receptor (CD87).
Magdolen V; Bürgle M; de Prada NA; Schmiedeberg N; Riemer C; Schroeck F; Kellermann J; Degitz K; Wilhelm OG; Schmitt M; Kessler H
Biol Chem; 2001 Aug; 382(8):1197-205. PubMed ID: 11592401
[TBL] [Abstract][Full Text] [Related]
38. Vitronectin binding to urokinase receptor in human breast cancer.
Carriero MV; Del Vecchio S; Franco P; Potena MI; Chiaradonna F; Botti G; Stoppelli MP; Salvatore M
Clin Cancer Res; 1997 Aug; 3(8):1299-308. PubMed ID: 9815812
[TBL] [Abstract][Full Text] [Related]
39. Analysis of the ternary complex formation of human urokinase with the separated two domains of its receptor.
Oda M; Shiraishi A; Hasegawa M
Eur J Biochem; 1998 Sep; 256(2):411-8. PubMed ID: 9760182
[TBL] [Abstract][Full Text] [Related]
40. Inhibition of urokinase activity and prevention of urokinase receptor binding by monoclonal antibodies.
Zacharias U; Handschack W; Schneider F; Löster K; Kleitke C; Noll F; Will H
J Immunol Methods; 1990 Jun; 130(1):81-90. PubMed ID: 2162894
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
